98%
921
2 minutes
20
Background: The intra-individual difference in cystatin C-based and creatinine-based estimated glomerular filtration rate (eGFRcys and eGFRcr, respectively), i.e. eGFR discordance, has recently been demonstrated to have prognostic implications. eGFR discordance was associated with mortality, cardiovascular and renal outcomes. We present a systematic review and meta-analysis to summarize the existing literature.
Methods: We searched PubMed, Embase and MEDLINE up to 28 April 2024 for cohort and cross-sectional studies in English reporting the association of eGFR discordance with mortality, cardiovascular and renal outcomes. The quality of studies was evaluated by Risk Of Bias In Non-randomized Studies-of Exposure (ROBINS-E) form. Data from studies were extracted to a pre-defined table and pooled using a random-effects model. Stratified and sensitivity analyses were performed.
Results: A total of 1489 studies were initially identified, of which 18 studies with longitudinal or cross-sectional designs were included, with a sample size between 373 and 363 494 people. In general, the risk of bias was graded as "low" or "some concerns". eGFR was mainly calculated using Chronic Kidney Disease Epidemiology Collaboration equations, while a few studies applied other equations. An eGFR discordance featuring lower eGFRcys, e.g. eGFRcys ≤60% of eGFRcr, or eGFRcys-eGFRcr ≤-15 mL/min/1.73 m, was consistently associated with higher mortality and elevated risk of cardiovascular and renal outcomes. People with lower eGFRcys have a 58% greater risk of mortality [hazard ratio (HR) = 1.58, 95% confidence interval (CI) 1.42, 1.76] and 32% greater risk of cardiovascular events (HR = 1.32, 95% CI 1.25, 1.39). People with higher eGFRcys have a 39% lower risk of mortality (HR = 0.61, 95% CI 0.52, 0.70) and 29% lower risk of cardiovascular events (HR = 0.71, 95% CI 0.62, 0.81). No meta-analysis for renal outcomes was conducted due to data availability.
Conclusions: The eGFR discordance serves as a meaningful indicator of adverse health outcomes. The lack of a consensus on the cut-off value of eGFR discordance and the mixture use of eGFR equations warrants attention.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11997436 | PMC |
http://dx.doi.org/10.1093/ckj/sfaf003 | DOI Listing |
J Pak Med Assoc
August 2025
Professor of Neurosurgery, Aga Khan University Hospital.
Breast cancer brain metastases (BCBM) are a significant clinical challenge, especially in aggressive subtypes like HER2-positive and triple-negative breast cancer. This review discusses hormone receptor discordance, it's existence and contributing factors, the role of the bloodbrain barrier (BBB) in metastatic progression, and therapeutic modalities. While local treatments such as surgery and radiotherapy remain foundational, advances in systemic and immunotherapeutic approaches show promising potential.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
August 2025
Department of Ophthalmology and Visual Sciences, University of New Mexico School of Medicine, Albuquerque, NM, United States.
Background: Although diabetic retinopathy (DR) and diabetic nephropathy (DN) are well known microvascular complications of diabetes, the correlation between DR and DN remains uncertain. Several studies have suggested differences in etiology and risk factors between these two complications.
Objectives: To examine whether diabetic retinopathy (DR) and nephropathy (DN) have significant concordance in terms of severity progression in patients with type 2 diabetes.
Res Vet Sci
October 2025
Animal and Veterinary Research Centre (CECAV), University of Trás-os-Montes and Alto Douro (UTAD), 5000-801 Vila Real, Portugal; Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS), University of Trás-os-Montes and Alto Douro (UTAD), 5000-801 Vila Real, Portugal. Electronic addres
Mammary tumors are the most prevalent neoplasms in intact female dogs; up to 50 % are considered malignant and have the potential to metastasize to regional lymph node and distant organs. Changes in tumor molecular subtype, including its receptor status, can occur during mammary tumor progression. This study aimed to explore hormone receptor discrepancies and the relationship between molecular subtypes in primary mammary tumors (PTs) and paired lymph node metastases (LNMs).
View Article and Find Full Text PDFJ Investig Med High Impact Case Rep
July 2025
Mass General Cancer Center at Wentworth-Douglass Hospital, Dover, NH, USA.
Breast cancer receptor status plays a critical role in treatment selection, yet receptor evolution throughout disease progression remains a significant challenge. This case describes a 58-year-old female initially diagnosed with estrogen receptor (ER)-positive (95%), progesterone receptor (PR)-negative (<5%), human epidermal growth factor receptor 2 (HER2)-negative (immunohistochemistry [IHC] 0, fluorescence in situ hybridization-negative) invasive ductal carcinoma. Over 6 years, her tumor transitioned to triple-negative breast cancer at recurrence, then reacquired ER expression (80%) in metastatic mediastinal lymph nodes.
View Article and Find Full Text PDFEur J Cancer
August 2025
Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
Introduction: We investigated the role of integrating tissue biopsy (TBx)- and liquid biopsy (LBx)-comprehensive genomic profiling (CGP) to predict the activity of FOLFIRI plus cetuximab.
Methods: The CAPRI-2 GOIM study is a non-randomized phase 2 study evaluating a biomarker-driven anti-EGFR treatment in three lines of therapy in patients with RAS/BRAF wild type metastatic colorectal cancer. At baseline, TBx and LBx were analyzed using the FoundationOne CDx platform.